Lupin To Present Cancer Drug Data at ASCO 2025
ECONOMY & POLICY

Lupin To Present Cancer Drug Data at ASCO 2025

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:
4. Date: 2 June 2025
5. Time: 1:30–4:30 pm CDT
6. Location: Hall A, McCormick Place, Chicago
7. Abstract No.: 3107 | Poster Board No.: 422
8. Trial Registration: CTRI/2023/07/054753
9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.Presentation Details:4. Date: 2 June 20255. Time: 1:30–4:30 pm CDT6. Location: Hall A, McCormick Place, Chicago7. Abstract No.: 3107 | Poster Board No.: 4228. Trial Registration: CTRI/2023/07/0547539. DOI: 10.1200/JCO.2025.43.16_suppl.3107Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code